WALTHAM, Mass.--Genome Therapeutics here announced that it acquired an exclusive license to proprietary genes regulated by the T53 tumor suppressor gene from Prince ton University. The agreement will enable Genome Therapeutics to develop proprietary targets within the p53 signal pathway that could lead to the identification of potential gene therapies and the development of new cancer treatments. Under terms of the agreement, Princeton will receive an undisclosed license fee and share in any product royalties created through future alliances.